Research Information System
IZMIR DR BEHCET UZ COCUK HASTANESI DERGISI, vol.4, no.3, pp.182-185, 2014 (ESCI, TRDizin)
Objective: To compare the safety and efficacy of 1.5% azithromycin eye drops with 0.3% netilmicin ophthalmic solution in a pediatric population with purulent bacterial conjunctivitis. Methods: Patients received either azithromycin (1.5%) (Group 1) (twice daily for 3 days) or netilmicin (0.3%) (Group 2) eye drops (four times daily for 7 days) to treat bacterial conjunctivitis. Clinical signs were evaluated on day 3 and 7. The primary variable was the clinical cure (absence of bulbar conjunctival injection and discharge) on day 3 for Group 1 and day 7 for Group 2. Results: A total of 92 patients were randomized, and both study medications were well tolerated. Clinical signs were evaluated on day 3 and 7. Clinical cure rate was similar between two groups (91.3% vs 89.3%, respectively). The most frequently observed ocular adverse events in the azithromycin group were eye irritation (15.2%) and conjunctival hyperemia (13.0%) in the netilmicin % 0.3 group. Conclusion: Despite their similar clinical responses in the treatment of children with bacterial conjunctivitis, azithromycin (1.5%) eye drops is safe and can be administered with a more convenient twice-a-day dosing regimen. when compared with netilmicin (0.3%) eye drops.